The most exciting data concern the morphologic evaluation of TILs, which have been demonstrated to be strongly prognostic in TNBC and early HER2+ BC patients treated with standard systemic therapy either in the adjuvant or neoadjuvant setting, as well as being predictive for the subsequent achievement of pCR in patients receiving standard neoadjuvant treatment in all BC subtypes. This evidence concerns the gene ERBB2 and breast cancer.